^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
QLS32015
i
Other names: QLS32015, QLS 32015, QLS-32015
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Qilu Pharma
Drug class:
CD3 agonist, GPRC5D inhibitor
Related drugs:
1m
Combination Therapy with QLS32015 for the Treatment of Multiple Myeloma (ChiCTR2500107567)
P2, N=160, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology
New P2 trial
|
lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • QLS32015
2ms
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma (clinicaltrials.gov)
P2, N=160, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • QLS32015 • dexamethasone injection
2ms
QLS32015: A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
New P1 trial
|
QLS32015
3ms
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P3, N=228, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
New P3 trial
|
Xpovio (selinexor) • pomalidomide • QLS32015
6ms
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma (clinicaltrials.gov)
P2, N=160, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
New P2 trial
|
lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • QLS32015 • dexamethasone injection
over2years
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=100, Recruiting, Qilu Pharmaceutical Co., Ltd.
New P1 trial
|
QLS32015
Share via
